September 2020

National Institute on Drug Abuse issues $1.7m SBIR Phase II Financial Award to EvON Medics.

On September 23, 2020, the National Institute on Drug Abuse at the National Institutes of Health issued Small Business innovation Research (SBIR) Phase II award of $1.7m to EvON Medics for the Development and Evaluation of its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for the treatment of Opioid Use Disorder. This is following a hugely successful SBIR Phase I study.

March 2020

EvON Medics completes successful Phase I clinical trials

March 2020, EvON Medics completes a successful Phase I clinical trials for its Computerized Olfactory Training Program (COT), developed for preventing the development and progression of Alzheimer’s Disease (AD) and its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), developed for the management of the Opioid Use Disorder (OUD). Both solutions are home-based and user-friendly neuromodulatory devices.

October 2018

National Institute on Aging Issues SBIR Financial Award to EvON Medics

On October 26, 2018, the National Institute on Aging at the National Institutes of Health issued Small Business innovation Research (SBIR) award to EvON Medics to support the development and evaluation of its computerized olfactory training program (COT) for cognitive decline in preclinical and early Alzheimer’s Disease (AD). COT is a key differentiating feature of the olfactory treatment delivery system (OTDS) platform developed by EvON Medics for treatment of a variety of brain conditions.